These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 32521502)

  • 1. Clinically relevant interaction of rivaroxaban and valproic acid - A case report.
    Langenbruch L; Meuth SG; Wiendl H; Mesters R; Möddel G
    Seizure; 2020 Aug; 80():46-47. PubMed ID: 32521502
    [No Abstract]   [Full Text] [Related]  

  • 2. Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight.
    Perales IJ; San Agustin K; DeAngelo J; Campbell AM
    Ann Pharmacother; 2020 Apr; 54(4):344-350. PubMed ID: 31672028
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
    Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
    Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rivaroxaban for the treatment of superficial vein thrombosis, experience at King's College Hospital.
    Clapham RE; Speed V; Czuprynska J; Gazes A; Guppy S; Patel RK; Rea C; Vadher B; Arya R; Roberts LN
    Br J Haematol; 2022 Jan; 196(1):e3-e6. PubMed ID: 34355385
    [No Abstract]   [Full Text] [Related]  

  • 5. Apixaban and rivaroxaban in patients with cerebral venous thrombosis.
    Covut F; Kewan T; Perez O; Flores M; Haddad A; Daw H
    Thromb Res; 2019 Jan; 173():77-78. PubMed ID: 30481600
    [No Abstract]   [Full Text] [Related]  

  • 6. Rivaroxaban after Thrombolysis in Acute Iliofemoral Venous Thrombosis: A Randomized, Open-labeled, Multicenter Trial.
    Kang JM; Park KH; Ahn S; Cho S; Han A; Lee T; Jung IM; Kim JY; Min SK
    Sci Rep; 2019 Dec; 9(1):20356. PubMed ID: 31889152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis.
    Lindner SM; Fordyce CB; Hellkamp AS; Lokhnygina Y; Piccini JP; Breithardt G; Mahaffey KW; Singer DE; Hacke W; Halperin JL; Hankey GJ; Berkowitz SD; Nessel CC; Becker RC; Fox KA; Patel MR;
    Circulation; 2017 Mar; 135(10):1001-1003. PubMed ID: 28264892
    [No Abstract]   [Full Text] [Related]  

  • 8. Rivaroxaban vs. warfarin on extended deep venous thromboembolism treatment: A cost analysis.
    Diken AI; Yalçınkaya A; Hanedan MO; Erol ME; Ercen Diken Ö
    Phlebology; 2018 Feb; 33(1):53-59. PubMed ID: 28056701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rivaroxaban for the treatment of cerebral venous thrombosis: a single-center experience.
    Bajko Z; Maier S; Motataianu A; Filep RC; Stoian A; Andone S; Balasa R
    Acta Neurol Belg; 2022 Feb; 122(1):105-111. PubMed ID: 33733345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rivaroxaban for the treatment and prevention of thromboembolic disease.
    Antoniou S
    J Pharm Pharmacol; 2015 Aug; 67(8):1119-32. PubMed ID: 26059702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe dizziness following rivaroxaban introduction in a parkinsonian patient: Drug-drug interaction?
    Lefaucheur R; Le Goff F; Gaillon G; Triquenot-Bagan A; Maltête D
    Presse Med; 2015 Nov; 44(11):1203-4. PubMed ID: 26433836
    [No Abstract]   [Full Text] [Related]  

  • 12. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
    Coleman CI; Bunz TJ; Turpie AGG
    Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low prevalence of Post-thrombotic syndrome in patients treated with rivaroxaban.
    Ferreira T; Huber SC; de Moraes Martinelli B; Junior AL; Menezes FH; Orsi FA; Bittar LF; de Oliveira LFG; Sodre LR; Mello TT; Rielli G; Colella MP; de Paula EV; Yamaguti-Hayakawa GG; Montalvão S; Annichino-Bizzacchi JM
    Vascul Pharmacol; 2020 Jan; 124():106608. PubMed ID: 31678199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New oral anticoagulants in patients with atrial fibrillation in a urban health center].
    Rodríguez Pérez L; Capilla Lozano F; Gallego Fuentes R; Buitrago F
    Med Clin (Barc); 2016 Mar; 146(6):280-1. PubMed ID: 26343157
    [No Abstract]   [Full Text] [Related]  

  • 15. Rivaroxaban in Chronic Hemodialysis Patients.
    Muster H; Alcorn H
    Am J Nephrol; 2016; 43(4):227-8. PubMed ID: 27100995
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparative Safety and Effectiveness of Oral Anticoagulants in Nonvalvular Atrial Fibrillation: The NAXOS Study.
    Van Ganse E; Danchin N; Mahé I; Hanon O; Jacoud F; Nolin M; Dalon F; Lefevre C; Cotté FE; Gollety S; Falissard B; Belhassen M; Steg PG
    Stroke; 2020 Jul; 51(7):2066-2075. PubMed ID: 32539675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The new oral anticoagulants: Reasonable alternatives to warfarin.
    Roca B; Roca M
    Cleve Clin J Med; 2015 Dec; 82(12):847-54. PubMed ID: 26651894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ischemic and Thrombotic Events Associated with Concomitant Xa-inhibiting Direct Oral Anticoagulants and Antiepileptic Drugs: Analysis of the FDA Adverse Event Reporting System (FAERS).
    Perlman A; Wanounou M; Goldstein R; Choshen Cohen L; Singer DE; Muszkat M
    CNS Drugs; 2019 Dec; 33(12):1223-1228. PubMed ID: 31686406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of Stroke Outcomes in Atrial Fibrillation Patients Treated with Rivaroxaban and Warfarin.
    Milentijevic D; Lin JH; Connolly N; Chen YW; Kogan E; Shrivastava S; Sjoeland E; Alberts MJ
    J Stroke Cerebrovasc Dis; 2021 May; 30(5):105715. PubMed ID: 33743312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.